Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Molecular Signatures Associated with Prolonged Survival In Melanoma Patients Treated with Dendritic Cell-Based Immunotherapy

ABSTRACT: Molecular Signatures Associated with Prolonged Survival In Melanoma Patients Treated with Dendritic Cell-Based Immunotherapy

PROVIDER: PRJNA415645 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Molecular Signatures Associated with Prolonged Survival In Melanoma Patients Treated with Dendritic Cell-Based Immunotherapy

Project description:Analysis of gene expression dynamics in patients suffering from melanoma stage IV treated with vaccination therapy.

2017-10-25 | GSE106128 | GEO

Treatment of dendritic cells and monocytes from immunotherapy treated patients with ONTAK

Project description:In this experiment, dendritic cells and monocytes obtained from melanoma patients who underwent immunotherapy were stimulated with a maturation cocktail then either treated or not treated with denlieukin diftitox (DD; ONTAK) and then subjected to transcription profiling to investigate the effects of DD on the maturation and activation of dendritic cells and monocytes.

2013-09-04 | E-MTAB-977 | biostudies-arrayexpress

In vivo dendritic cell reprogramming for cancer immunotherapy [organoid scRNA]

Project description:Immunotherapy can lead to long-term survival for some cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach to reprogram tumor cells in vivo by adenoviral delivery of the transcription factors PU.1, IRF8, and BATF3, which enabled them to present antigens as type 1 conventional dendritic cells. Reprogrammed tumor cells remodeled their tumor microenvironment, recruited, and expanded polyclonal cytotoxic T cells, induced tumor regressions, and established long-term systemic immunity in multiple mouse melanoma models. In human tumor spheroids and xenografts, reprogramming to immunogenic dendritic-like cells progressed independently of immunosuppression, which usually limits immunotherapy. Our study paves the way for human clinical trials of in vivo immune cell reprogramming for cancer immunotherapy.

2024-09-05 | GSE255536 | GEO

In vivo dendritic cell reprogramming for cancer immunotherapy [T cell scRNA + TCR]

2024-09-05 | GSE255385 | GEO

Propafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma

Project description:Despite the successful application of immunotherapy, both innate and acquired resistance are typical in melanoma. Ferroptosis induction appears to be a potential strategy to enhance the effectiveness of immunotherapy. However, the relationship between the status of ferroptosis and the effectiveness of immunotherapy, as well as viable strategies to augment ferroptosis, remain unclear. In this study, through large-scale drug screening of cardiovascular drugs, we identified propafenone, an anti-arrhythmia medication, as capable of synergizing with ferroptosis inducers in melanoma. Furthermore, we observed that propafenone, in combination with RSL3, collaboratively induces mitochondrial-associated ferroptosis. Mechanistically, propafenone transcriptionally upregulates mitochondrial HMOX1 via activation of the JNK/JUN signaling pathway under RSL3 treatment, leading to overloaded ferrous iron and ROS within the mitochondria. In xenograft models, the combination of propafenone with ferroptosis induction led to nearly complete tumor regression. Consistently, propafenone enhances immunotherapy-induced antitumor immunity and tumoral ferroptosis in tumor-bearing mice. Significantly, patients exhibiting high levels of ferroptosis/JUN/HMOX1 exhibited improved efficacy of immunotherapy and prolonged progression-free survival. These findings suggest that propafenone holds promise as a candidate drug for enhancing the efficacy of immunotherapy and other ferroptosis-targeted therapies in the treatment of melanoma.

2024-10-26 | GSE279924 | GEO

Tertiary Lymphoid Structure Raises Survival and Immunotherapy in HPV- HNSCC

Project description:Tertiary Lymphoid Structure Raises Survival and Immunotherapy in HPV- HNSCC

| PRJNA810974 | ENA

In vivo dendritic cell reprogramming for cancer immunotherapy [organoid scRNA]

Project description:In vivo dendritic cell reprogramming for cancer immunotherapy [organoid scRNA]

| PRJNA1075314 | ENA

Cytokine-armored dendritic cell progenitors for antigen-agnostic cancer immunotherapy

Project description:Cytokine-armored dendritic cell progenitors for antigen-agnostic cancer immunotherapy

| PRJNA948418 | ENA

A Molecular Signature associated with prolonged survival in Glioblastoma patients treated with Regorafenib

Project description:A Molecular Signature associated with prolonged survival in Glioblastoma patients treated with Regorafenib

| PRJNA644916 | ENA

Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients.

Project description:Efficacy of cancer vaccines remains low and mechanistic understanding of antigen presenting cell function in cancer may improve vaccine design and outcomes. Here, we analyze the transcriptomic and immune-metabolic profiles of Dendritic Cells (DCs) from 35 subjects enrolled in a trial of DC vaccines in late-stage melanoma (NCT01622933). Multiple platforms identify metabolism as an important biomarker of DC function and patient overall survival (OS). We demonstrate multiple immune and metabolic gene expression pathway alterations, a functional decrease in OCR/OXPHOS and increase in ECAR/glycolysis in patient vaccines. To dissect molecular mechanisms, we utilize single cell SCENITH functional profiling and show patient clinical outcomes (OS) correlate with DC metabolic profile, and that metabolism is linked to immune phenotype. With single cell metabolic regulome profiling, we show that MCT1 (monocarboxylate transporter-1), a lactate transporter, is increased in patient DCs, as is glucose uptake and lactate secretion. Importantly, pre-vaccination circulating myeloid cells in patients used as precursors for DC vaccine generation are significantly skewed metabolically as are several DC subsets. Together, we demonstrate that the metabolic profile of DC is tightly associated with the immunostimulatory potential of DC vaccines from cancer patients. We link phenotypic and functional metabolic changes to immune signatures that correspond to suppressed DC differentiation.

| S-EPMC10632482 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data